New therapeutic agents in the management of HIV: An overview of darunavir for clinicians

Jessica Rotty, Jennifer Hoy

Research output: Contribution to journalReview ArticleResearchpeer-review

4 Citations (Scopus)


This overview will provide the reader with summarised information about darunavir, a new protease inhibitor licenced for the treatment of drug resistant HIV-infection. Darunavir is a promising new drug with good clinical efficacy data and safety profile. In this overview clinicians will be updated on clinical efficacy data, side-effects, resistance profile and drug interactions. The overview should give clinicians a sound understanding of when and how to use this new protease inhibitor in the treatment of HIV-infection.

Original languageEnglish
Pages (from-to)235-241
Number of pages7
JournalSexual Health
Issue number3
Publication statusPublished - 20 Aug 2008


  • Drug resistance
  • Prezista
  • Protease inhibitor

Cite this